Literature DB >> 21443701

Functional gastrointestinal disorders in New Zealand.

John W Wyeth1.   

Abstract

BACKGROUND: Functional gastrointestinal disorders are common worldwide. AIM: To review functional gastrointestinal disorder prevalence, diagnosis and treatment in New Zealand.
METHODS: A Medline search was performed to identify all published studies relating to prevalence, diagnosis and treatment of functional gastrointestinal disorders in New Zealand.
RESULTS: Reflux prevalence is 30% and non-reflux dyspepsia is 34.2%. Helicobacter pylori prevalence varies considerably in NZ by geographical area and ethnicity and overall prevalence of infection is 24% in adults. 50% of patients with dyspepsia presenting for endoscopy in NZ will have no mucosal abnormality identified. National Dyspepsia Guidelines assist in management of patients. Guidelines exist for undifferentiated dyspepsia, Gastro-oesophageal Reflux Disease (GORD), H. pylori, peptic ulcer, NSAID's and gastrointestinal complications. Irritable Bowel Syndrome (IBS) is reported by 21% of adults. Symptoms were more than twice as frequent and severe in females than males. Access to colonoscopy for investigation of bowel symptoms is limited in NZ and priority is given to patients with "alarm features". Non-invasive markers of inflammation, such as faecal calprotectin, are being used to differentiate the patient with functional diarrhoea from inflammatory bowel disease. Treatment for irritable bowel symptoms is targeted to the predominant symptom.
CONCLUSIONS: Functional gastrointestinal disorders are common in New Zealand. There is increasing awareness of dietary management for functional bowel symptoms.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21443701     DOI: 10.1111/j.1440-1746.2011.06645.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.

Authors:  Leonel Rodriguez; Juan Diaz; Samuel Nurko
Journal:  J Pediatr       Date:  2013-02-16       Impact factor: 4.406

2.  Cohort Profile: The Christchurch IBS cOhort to investigate Mechanisms FOr gut Relief and improved Transit (COMFORT).

Authors:  Phoebe Heenan; Rob H Creemers; Shriya Sharma; Jacqueline Keenan; Simone Bayer; Wayne Young; Janine Cooney; Kelly Armstrong; Karl Fraser; Paula M Skidmore; Nicholas J Talley; Nicole Roy; Richard B Gearry
Journal:  Inflamm Intest Dis       Date:  2020-07-08

3.  What Does the Excised Stomach from Sleeve Gastrectomy Tell us?

Authors:  Melanie Lauti; Sophie E Gormack; Jeni M Thomas; Jon J Morrow; Habib Rahman; Andrew D MacCormick
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

4.  Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults.

Authors:  Ammar Hassanzadeh Keshteli; Babak Dehestani; Hamed Daghaghzadeh; Peyman Adibi
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

5.  Variation in gastric pH may determine kiwifruit's effect on functional GI disorder: an in vitro study.

Authors:  Bruce Donaldson; Elaine Rush; Owen Young; Ray Winger
Journal:  Nutrients       Date:  2014-04-11       Impact factor: 5.717

6.  The Manufacturing Process of Kiwifruit Fruit Powder with High Dietary Fiber and Its Laxative Effect.

Authors:  Ziqi Zhuang; Min Chen; Jihan Niu; Na Qu; Bing Ji; Xiang Duan; Zhande Liu; Xuebo Liu; Yutang Wang; Beita Zhao
Journal:  Molecules       Date:  2019-10-23       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.